Silencing a SIRT4-like mitochondrial gene worsens Parkinson's-like pathology in worms

Parkinson's disease is a progressive, age-associated disorder marked by alpha-synuclein aggregation and loss of dopamine-producing neurons. Current drugs manage symptoms but do not stop the disease. Mitochondrial disruption is a recognised hallmark of ageing and neurodegeneration, and sirtuins, NAD+-dependent deacetylases linked to longevity, regulate mitochondrial metabolism and stress responses. Mitochondrial sirtuins have been less studied than SIRT1 in this setting, which motivated this work.

The team used Caenorhabditis elegans, which has two mitochondrial sirtuin genes, sir-2.2 and sir-2.3. An initial screen showed that knocking down sir-2.2 reduced mitochondrial content more prominently, so they focused on it. sir-2.2 is the orthologue of human SIRT4. They silenced it by RNAi in several transgenic strains and compared results with empty-vector controls. NL5901 expresses alpha-synuclein tagged with YFP in muscle. BY250 carries a dat-1 promoter-driven GFP reporter in dopaminergic neurons. UA44 expresses alpha-synuclein in dopaminergic neurons alongside the GFP reporter. Readouts included fluorescence imaging, western blotting, real-time PCR, and behavioural assays (thrashing and 1-nonanol aversion). Comparisons used unpaired two-tailed t-tests.

sir-2.2 knockdown increased alpha-synuclein fluorescence in NL5901 worms about 1.4-fold (13.91 vs 9.95), and western blotting showed roughly a 2-fold rise in alpha-synuclein protein. In BY250 worms, dat-1 reporter fluorescence fell about 1.3-fold (2.75 vs 3.38), and dat-1 mRNA dropped 4.4-fold. In UA44 worms, where alpha-synuclein is present in dopaminergic neurons, reporter signal at day 7 was 1.46-fold lower than in BY250 worms, which the authors interpret as dopaminergic neuron degeneration and reduced dopamine. Behavioural assays were run in wild-type N2, NL5901 and UA44 worms, but those results were not available in the text provided.

The abstract also reports that sir-2.2 knockdown lowered markers of innate immunity, oxidative stress response, mitophagy, the mitochondrial unfolded protein response and autophagy, with energy homeostasis impaired. Together these point to a role for sir-2.2 in mitochondrial quality control and protein clearance. The authors conclude that mitochondrial sirtuins deserve attention as therapeutic targets for the metabolic regulation of ageing and neurodegeneration.

These are preclinical findings from a nematode, and knockdown shows that losing the gene is harmful, not that boosting it is protective. Much of the evidence comes from fluorescence reporters, which are indirect proxies for protein levels and neuron health. Translation to human SIRT4 biology, which is less well characterised than other sirtuins, remains unproven. The text supplied for this summary was truncated, so details of the behavioural, energetics, mitophagy and stress-response experiments could not be verified beyond the abstract.